In-Vitro Colorectal Cancer Screening Tests Market Analysis By Product (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Tumor M2-PK Stool Test, Transferrin Assays, Methylated Gene Testing, Panel DNA Tests) And Segment Forecasts to 2022

Table of Content

Chapter 1 Methodology and Scope
                  1.1 Research Methodology
                  1.2 Research Scope & Assumptions
                  1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 In-Vitro Colorectal Cancer Screening Tests Industry Outlook
                  3.1 Market segmentation
                  3.2 Market size and growth prospects
                  3.3 In-Vitro Colorectal Cancer Screening Tests: Market dynamics
                     3.3.2 Market driver analysis
                         3.3.2.1 Growing incidence of colon and rectal cancers
                         3.3.2.2 Growing accuracy of colorectal cancer screening by use of genetic testing
                         3.3.2.3 Presence of a number of colorectal cancer screening products in pipeline
                     3.3.3 Market restraint analysis
                         3.3.3.1 Pending investigational evidence for certain genetic screening tests
                         3.3.3.2 Difficulty to undertake CRC screening tests to encompass the entire
                         3.3.3.3 Lack of cancer screening guideless in Asia Pacific region
                  3.4 Industry Analysis - Porter’s
                  3.5 Key opportunities prioritized
                  3.6 In-Vitro Colorectal Cancer Screening Tests market - PESTEL analysis
Chapter 4 In-Vitro Colorectal Cancer Screening Tests Product Outlook
                  4.1 In-vitro colorectal cancer screening tests market share by test type, 2014 & 2022
                  4.2 Fecal Occult Blood Tests
                     4.2.1 Fecal occult blood tests market, 2012 - 2022 (USD Million)
                     4.2.2 Guaiac FOB Stool Test
                         4.2.2.1 Guaiac FOB stool tests market, 2012 - 2022 (USD Million)
                     4.2.3 Immuno-FOB agglutination test
                         4.2.3.1 Immuno-FOB agglutination tests market, 2012 - 2022 (USD Million)
                     4.2.4 Lateral Flow Immuno-FOB Test
                         4.2.4.1 Lateral flow Immuno-FOB tests market, 2012 - 2022 (USD Million)
                     4.2.5 Immuno-FOB ELISA test
                         4.2.5.1 Immuno-FOB ELISA tests market, 2012 - 2022 (USD Million)
                  4.3 Biomarker tests market
                     4.3.2 Tumor M2-PK Stool Test
                         4.3.2.1 Tumor M2-PK stool tests market, 2012 - 2022 (USD Million)
                     4.3.3 Transferrin assays
                         4.3.3.1 Transferrin assays market, 2012 - 2022 (USD Million)
                  4.4 CRC DNA screening tests
                     4.4.1 CRC DNA screening tests market, 2012 - 2022, (USD Million)
                     4.4.2 Methylated Gene Testing
                         4.4.2.1 Methylated gene testing market, 2012 - 2022 (USD Million)
                     4.4.3 Panel DNA Tests
                         4.4.3.1 Panel DNA tests market, 2012 - 2022 (USD Million)
Chapter 5 In-vitroColorectal Cancer Screening Tests Regional Outlook
                  5.1 In-vitro colorectal cancer screening tests market share by region, 2014 & 2022
                  5.2 North America
                     5.2.1 North America market, by product, 2012 - 2022 (USD Million)
                     5.2.2 U.S. market, by product, 2012 - 2022 (USD Million)
                     5.2.3 Canada market, by product, 2012 - 2022 (USD Million)
                  5.3 Europe
                     5.3.1 Europe market, by product, 2012 - 2022 (USD Million)
                     5.3.2 Germany market, by product, 2012 - 2022 (USD Million)
                     5.3.3 UK market, by product, 2012 - 2022 (USD Million)
                  5.4 Asia Pacific
                     5.4.1 Asia Pacific market, by product, 2012 - 2022 (USD Million)
                     5.4.2 Japan market, by product, 2012 - 2022 (USD Million)
                     5.4.3 China market, by product, 2012 - 2022 (USD Million)
                  5.5 Latin America
                     5.5.1 Latin America market, by product, 2012 - 2022 (USD Million)
                     5.5.2 Brazil market, by product, 2012 - 2022 (USD Million)
                     5.5.3 Mexico market, by product, 2012 - 2022 (USD Million)
                  5.6 MEA
                     5.6.1 MEA market, by product, 2012 - 2022 (USD Million)
                     5.6.2 South Africa market, by product, 2012 - 2022 (USD Million)
Chapter 6 Competitive Landscape
                  6.1 Abbott Molecular Inc
                     6.1.1 Company Overview
                     6.1.2 Financial Performance
                     6.1.3 Product Benchmarking
                     6.1.4 Strategic Initiatives
                  6.2 Alere Inc.
                     6.2.1 Company Overview
                     6.2.2 Financial Performance
                     6.2.3 Product Benchmarking
                     6.2.4 Strategic Initiatives
                  6.3 Beckman Coulter Inc
                     6.3.1 Company Overview
                     6.3.2 Financial Performance
                     6.3.3 Product Benchmarking
                  6.4 Eiken Chemical
                     6.4.1 Company Overview
                     6.4.2 Financial Performance
                     6.4.3 Product Benchmarking
                     6.4.4 Strategic Initiatives
                  6.5 Epigenomics AG Corporation
                     6.5.1 Company Overview
                     6.5.2 Financial Performance
                     6.5.3 Product Benchmarking
                     6.5.4 Strategic Initiatives
                  6.6 Sysmex Corporation
                     6.6.1 Company Overview
                     6.6.2 Financial Performance
                     6.6.3 Product Benchmarking
                     6.6.4 Strategic Initiatives
                  6.7 Siemens Healthcare Ltd.
                     6.7.1 Company Overview
                     6.7.2 Financial Performance
                     6.7.3 Product Benchmarking
                  6.8 Quest Diagnostics Incorporated
                     6.8.1 Company Overview
                     6.8.2 Financial Performance
                     6.8.3 Product Benchmarking
                     6.8.4 Strategic Initiatives
                  6.9 CompanianDx
                     6.9.1 Company Overview
                     6.9.2 Financial Performance
                     6.9.3 Product Benchmarking
                     6.9.4 Strategic Initiatives
                  6.10 OncoCyte Corporation-Biotime
                     6.10.1 Company Overview
                     6.10.2 Financial Performance
                     6.10.3 Product Benchmarking
                     6.10.4 Strategic Initiatives
                  6.11 Merck Millipore
                     6.11.1 Company Overview
                     6.11.2 Financial Performance
                     6.11.3 Product Benchmarking
                     6.11.4 Strategic Initiatives
                  6.12 GeneNews Ltd.
                     6.12.1 Company Overview
                     6.12.2 Financial Performance
                     6.12.3 Product Benchmarking
                     6.12.4 Strategic Initiatives
                  6.13 BioMarCare Technologies Ltd.
                     6.13.1 Company Overview
                     6.13.2 Financial Performance
                     6.13.3 Product Benchmarking
                     6.13.4 Strategic Initiatives
                  6.14 Immunostics Inc.
                     6.14.1 Company Overview
                     6.14.2 Financial Performance
                     6.14.3 Product Benchmarking
                  6.15 Exiqon
                     6.15.1 Company Overview
                     6.15.2 Financial Performance
                     6.15.3 Product Benchmarking
                     6.15.4 Strategic Initiatives
                  6.16 Kyowa Medex Co. Ltd.
                     6.16.1 Company Overview
                     6.16.2 Financial Performance
                     6.16.3 Product Benchmarking
                     6.16.4 Strategic Initiatives
                  6.17 Mode Diagnostics
                     6.17.1 Company Overview
                     6.17.2 Financial Performance
                     6.17.3 Product Benchmarking
                     6.17.4 Strategic Initiatives
                  6.18 Randox Laboratories Ltd.
                     6.18.1 Company Overview
                     6.18.2 Financial Performance
                     6.18.3 Product Benchmarking
                     6.18.4 Strategic Initiatives
                  6.19 R-Biopharm Incorporation
                     6.19.1 Company Overview
                     6.19.2 Financial Performance
                     6.19.3 Product Benchmarking
                     6.19.4 Strategic Initiatives

List of Tables

TABLE 1 In-Vitro Colorectal Cancer Screening Tests Market - Industry Summary & Key Buying Criteria
TABLE 2 Global market, by test type, 2012 - 2022 (USD Million)
TABLE 3 Global market, by region, 2012 - 2022 (USD Million)
TABLE 4 In-Vitro Colorectal Cancer Screening Tests - Key market driver analysis
TABLE 5 In-Vitro Colorectal Cancer Screening Tests - Key market restraint analysis
TABLE 6 North America market by test type, 2012 - 2022 (USD Million)
TABLE 7 North America fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 8 North America biomarker tests market, 2012 - 2022 (USD Million)
TABLE 9 North America CRA DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 10 U.S. market by test type, 2012 - 2022 (USD Million)
TABLE 11 U.S. fecal occult blood test market, 2012 - 2022 (USD Million)
TABLE 12 U.S biomarker test market, 2012 - 2022 (USD Million)
TABLE 13 U.S. CRC DNA screening test market, 2012 - 2022 (USD Million)
TABLE 14 Canada market by test type, 2012 - 2022 (USD Million)
TABLE 15 Canada fecal occult blood test market, 2012 - 2022 (USD Million)
TABLE 16 Canada CRC DNA screening test market, 2012 - 2022 (USD Million)
TABLE 17 Canada biomarker test market, 2012 - 2022 (USD Million)
TABLE 18 Europe market by test type, 2012 - 2022 (USD Million)
TABLE 19 Europe fecal occult blood test market, 2012 - 2022 (USD Million)
TABLE 20 Europe biomarker test market, 2012 - 2022 (USD Million)
TABLE 21 Europe CRC DNA screening test market, 2012 - 2022 (USD Million)
TABLE 22 Germany market by test type, 2012 - 2022 (USD Million)
TABLE 23 Germany fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 24 Germany biomarker tests market, 2012 - 2022 (USD Million)
TABLE 25 Germany CRC DNA screening test, 2012 - 2022 (USD Million)
TABLE 26 UK market by test type, 2012 - 2022 (USD Million)
TABLE 27 UK fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 28 UK biomarker tests market, 2012 - 2022 (USD Million)
TABLE 29 UK CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 30 Asia Pacific market by test type, 2012 - 2022 (USD Million)
TABLE 31 Asia Pacific fecal occult blood tests, 2012 - 2022 (USD Million)
TABLE 32 Asia Pacific biomarker tests, 2012 - 2022 (USD Million)
TABLE 33 Asia Pacific CRC DNA screening tests, 2012 - 2022 (USD Million)
TABLE 34 Japan market by test type, 2012 - 2022 (USD Million)
TABLE 35 Japan fecal occult tests market 2012 - 2022 (USD Million)
TABLE 36 Japan biomarker tests market 2012 - 2022 (USD Million)
TABLE 37 Japan CRC DNA screening tests market 2012 - 2022 (USD Million)
TABLE 38 China market by test type, 2012 - 2022 (USD Million)
TABLE 39 China fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 40 China biomarker tests market, 2012 - 2022 (USD Million)
TABLE 41 China CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 42 Latin America market by test type, 2012 - 2022 (USD Million)
TABLE 43 Latin America fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 44 Latin America biomarker tests market, 2012 - 2022 (USD Million)
TABLE 45 Latin America CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 46 Brazil market by product, 2012 - 2022 (USD Million)
TABLE 47 Brazil fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 48 Brazil biomarker tests market, 2012 - 2022 (USD Million)
TABLE 49 Brazil CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 50 Mexico market by test type, 2012 - 2022 (USD Million)
TABLE 51 Mexico fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 52 Mexico biomarker tests market, 2012 - 2022 (USD Million)
TABLE 53 Mexico CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 54 MEA market by test type, 2012 - 2022 (USD Million)
TABLE 55 MEA fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 56 MEA biomarker tests market, 2012 - 2022 (USD Million)
TABLE 57 MEA CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 58 South Africa by test types, 2012 - 2022 (USD Million)
TABLE 59 South Africa fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 60 South Africa biomarker tests market, 2012 - 2022 (USD Million)
TABLE 61 South Africa CRC DNA screening tests market, 2012 - 2022 (USD Million)

List of Figures

FIG. 1 In-vitro colorectal cancer screening tests: Market segmentation
FIG. 2 Global market, (USD Million), 2012 - 2022
FIG. 3 In-Vitro Colorectal Cancer Screening Tests: Market dynamics
FIG. 4 In-Vitro Colorectal Cancer Screening Tests market - Porter’s Analysis
FIG. 5 Key opportunities prioritized, 2014
FIG. 6 In-vitro colorectal cancer screening tests market - PESTEL analysis
FIG. 7 In-vitro colorectal cancer screening tests market share by test type, 2014 & 2022
FIG. 8 Global fecal occult blood tests market, 2012 - 2022 (USD Million)
FIG. 9 Global guaiac FOB stool tests market, 2012 - 2022 (USD Million)
FIG. 10 Immuno-FOB agglutination tests market, 2012 - 2022 (USD Million)
FIG. 11 Lateral flow immuno-FOB tests market, 2012 - 2022 (USD Million)
FIG. 12 Immuno-FOB ELISA tests market, 2012 - 2022 (USD Million)
FIG. 13 Global biomarker tests market, 2012 - 2022 (USD Million)
FIG. 14 Tumor M2-PK stool tests, 2012 - 2022 (USD Million)
FIG. 15 Transferrin assays market, 2012 - 2022 (USD Million)
FIG. 16 Global CRC DNA screening tests market, 2012 - 2022 (USD Million)
FIG. 17 Methylated gene testing market, 2012 - 2022 (USD Million)
FIG. 18 Panel DNA tests market, 2012 - 2022 (USD Million)
FIG. 19 In-vitro colorectal cancer screening tests market share by region, 2014 & 2022
FIG. 20 North America market, 2012 - 2022 (USD Million)
FIG. 21 U.S. in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 22 Canada in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 23 Europe in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 24 Germany in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 25 UK in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 26 Asia Pacific in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 27 Japan in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 28 China in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 29 Latin America In-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 30 Brazil in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 31 Mexico In-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 32 MEA in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 33 South Africa in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)